- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso | ||
| Di | The Oral GLP-1 Tracker: Following the launch trajectories of Lilly's Foundayo, Novo's Wegovy pill | ||
| Di | Pfizer's strategy head Andrew Baum to step down following brief tenure: reports | ||
| Di | AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win | ||
| Di | In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer | ||
| Di | UCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition deserts | ||
| Mo | Genentech shifts Hemlibra marketing focus to patient stories as competition approaches | ||
| Mo | Neurogene hires new CCO as it eyes commercial future for its Rett gene therapy | ||
| Mo | Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike | ||
| Mo | Biovac nets $108M finance package to build Africa's first fully integrated vaccine plant | ||
| Mo | Biogen bullish on America with Durham Bulls team up | ||
| Mo | Bayer falls short in bid to block J&J's survival claims in prostate cancer clash | ||
| Mo | AbbVie launches 'PSO Done' psoriasis campaign with cross-agency effort | ||
| Mo | Theramex exits self-regulatory body after 'systemic' compliance failures | ||
| 17.04. | FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER | ||
| 17.04. | Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat | ||
| 17.04. | Fierce Pharma Asia-Astellas' stem cell therapy rethink; GSK's bullish ADC plan; Daiichi's OTC sale | ||
| 17.04. | BIO comes out swinging with 'Fight of Our Lives' campaign for the industry's 50th birthday | ||
| 16.04. | Viatris, Teva kick off separate recalls over dissolution, raw material issues | ||
| 16.04. | 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again | ||
| 16.04. | Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy | ||
| 16.04. | Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel | ||
| 16.04. | Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover | ||
| 15.04. | In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory | ||
| 15.04. | Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.